Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $58 to $64.
January 18, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Intra-Cellular Therapies but raises the price target from $58 to $64, indicating a positive outlook on the stock's value.
The increase in price target by a reputable analyst like Goldman Sachs suggests a positive reassessment of Intra-Cellular Therapies' stock value, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100